SEC Form 4 · accession 0001079462-26-000006
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen A Sherwin
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 5:40 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2026 | M | 15,000 | $53.64 | A | 30,860 | D | |
| Common Stock | Jun 5, 2026 | M | 10,000 | $79.79 | A | 40,860 | D | |
| Common StockF2 | Jun 5, 2026 | S | 7,883 | $163.807 | D | 32,977 | D | |
| Common StockF3 | Jun 5, 2026 | S | 2,549 | $164.4394 | D | 30,428 | D | |
| Common StockF4 | Jun 5, 2026 | S | 6,896 | $165.7926 | D | 23,532 | D | |
| Common StockF5 | Jun 5, 2026 | S | 5,829 | $166.5567 | D | 17,703 | D | |
| Common StockF6 | Jun 5, 2026 | S | 1,843 | $167.3128 | D | 15,860 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF7 | $53.64 | Jun 5, 2026 | M | 15,000 | D | — | May 22, 2027 | Common Stock | 15,000 | 0 | D |
| Non-Qualified Stock OptionF8 | $79.79 | Jun 5, 2026 | M | 10,000 | D | — | May 22, 2029 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.11 to $164.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.11 to $164.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.11 to $166.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.11 to $167.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.11 to $167.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017.
- F8The option was granted May 22, 2019 and vested in 12 equal monthly installments beginning June 22, 2019.